AI assistant
HAEMONETICS CORP — Director's Dealing 2023
May 17, 2023
31565_dirs_2023-05-17_9da6f0de-02a4-4e3d-812a-ad8faabf4eeb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2023-05-15
Reporting Person: Llorens Josep (EVP, Global Manufacturing)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-05-15 | Common Stock | A | 3084 | — | Acquired | 20205 | Direct |
| 2023-05-16 | Common Stock | F | 319 | $89.21 | Disposed | 19886 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-05-15 | Non-qualified Stock Option (Right to Buy) | $89.16 | A | 6968 | Acquired | 2030-05-15 | Common Stock (6968) | Direct |
Footnotes
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3: This number includes unvested RSUs previously reported.
F4: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
F5: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.